KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Non Operating Income (2021 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Non Operating Income for 5 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 36.51% to $5.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.2 million through Dec 2025, down 31.07% year-over-year, with the annual reading at $28.2 million for FY2025, 31.07% down from the prior year.
  • Non Operating Income for Q4 2025 was $5.0 million at Xenon Pharmaceuticals, down from $6.1 million in the prior quarter.
  • The five-year high for Non Operating Income was $11.5 million in Q1 2024, with the low at -$2.7 million in Q1 2022.
  • Average Non Operating Income over 5 years is $5.8 million, with a median of $7.3 million recorded in 2022.
  • The sharpest move saw Non Operating Income soared 3023.55% in 2022, then tumbled 42.11% in 2025.
  • Over 5 years, Non Operating Income stood at -$242000.0 in 2021, then skyrocketed by 3023.55% to $7.1 million in 2022, then grew by 23.63% to $8.7 million in 2023, then dropped by 9.18% to $7.9 million in 2024, then crashed by 36.51% to $5.0 million in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $5.0 million, $6.1 million, and $8.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.